SPRY insider transaction filings
ARS Pharmaceuticals, Inc. — 44 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-02. Screen SPRY transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Casale Donn — President | Grant/award (A): 898,456 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Kelly Michael — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Dadoo Rajeev — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Shah Pratik — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Islam Saqib — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Shawver Laura — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Thompson Peter A. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | SAUNDERS BRENT L — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | SCHNEIDER PHILLIP M — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Karas Eric — Chief Commercial Officer | Option exercise (M): 25,000 @ $1.50 · Sale (S): 25,000 @ $10 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Fitzpatrick Alexander A — Chief Legal Officer | Sale (S): 3,355 @ $10 | EDGAR |
| 2026-01-05 | 4 | Tanimoto Sarina — CHIEF MEDICAL OFFICER, 10% owner | Grant/award (A): 240,000 (derivative) @ $0 · Grant/award (A): 875,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Karas Eric — Chief Commercial Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Chakma Justin — Chief Business Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Scott Kathleen D. — Chief Financial Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Fitzpatrick Alexander A — Chief Legal Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Dorsey Brian — Chief Operating Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Lowenthal Richard E — PRESIDENT AND CEO, Director, 10% owner | Grant/award (A): 875,000 (derivative) @ $0 · Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Chakma Justin — Chief Business Officer | Option exercise (M): 30,000 @ $0.84 · Sale (S): 30,000 @ $8.91 · Sale (S): 136,380 @ $8.86 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Shah Pratik — Director | Gift (G): 250,000 @ $0 · Gift (G): 100,000 @ $0 | EDGAR |
| 2025-11-14 | 4 | Dorsey Brian — Chief Operating Officer | Option exercise (M): 21,828 @ $0.64 · Sale (S): 21,828 @ $8.71 · Option exercise (M): 21,828 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Scott Kathleen D. — Chief Financial Officer | Option exercise (M): 12,500 @ $1.50 · Sale (S): 12,500 @ $15 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Lowenthal Richard E — PRESIDENT AND CEO, Director, 10% owner | Sale (S): 50,000 @ $14.49 | EDGAR |
| 2025-08-21 | 4 | Tanimoto Sarina — CHIEF MEDICAL OFFICER, 10% owner | Sale (S): 12,344 @ $14.03 · Sale (S): 37,656 @ $14.09 | EDGAR |
| 2025-07-03 | 4 | Karas Eric — Chief Commercial Officer | Option exercise (M): 15,000 @ $1.50 · Sale (S): 15,000 @ $16.99 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Flynn James E — 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — 10% owner Deerfield Mgmt III, L.P. — 10% owner Deerfield Private Design Fund III, L.P. — 10% owner Deerfield Mgmt IV, L.P. — 10% owner Deerfield Private Design Fund IV, L.P. — 10% owner | Sale (S): 370,075 @ $18.46 · Sale (S): 370,074 @ $18.46 | EDGAR |
| 2025-06-27 | 4 | Kelly Michael — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Dadoo Rajeev — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Shah Pratik — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Islam Saqib — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Shawver Laura — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Thompson Peter A. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | SAUNDERS BRENT L — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | SCHNEIDER PHILLIP M — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Karas Eric — Chief Commercial Officer | Option exercise (M): 15,000 @ $1.50 · Sale (S): 15,000 @ $16 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Scott Kathleen D. — Chief Financial Officer | Option exercise (M): 50,000 @ $1.50 · Sale (S): 50,000 @ $14.10 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Fitzpatrick Alexander A — Chief Legal Officer | Option exercise (M): 100,000 @ $5.58 · Sale (S): 102,969 @ $14.10 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | SAUNDERS BRENT L — Director | Option exercise (M): 120,000 @ $1.01 · Sale (S): 120,000 @ $14.25 · Option exercise (M): 120,000 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4 | Shawver Laura — Director | Option exercise (M): 22,509 @ $4.85 · Option exercise (M): 27,493 @ $4.85 · Sale (S): 50,002 @ $12.30 · Option exercise (M): 22,509 (derivative) @ $0 · Option exercise (M): 27,493 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Karas Eric — Chief Commercial Officer | Option exercise (M): 10,000 @ $1.50 · Sale (S): 10,000 @ $14 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Shawver Laura — Director | Option exercise (M): 400 @ $4.85 · Sale (S): 400 @ $11 · Option exercise (M): 49,600 @ $4.85 · Sale (S): 49,600 @ $11.21 · Option exercise (M): 400 (derivative) @ $0 · Option exercise (M): 49,600 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Shawver Laura — Director | Option exercise (M): 9,064 @ $3.15 · Option exercise (M): 40,936 @ $4.85 · Sale (S): 50,000 @ $12.31 · Option exercise (M): 9,064 (derivative) @ $0 · Option exercise (M): 40,936 (derivative) @ $0 | EDGAR |
Recent 8-K events — ARS Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-28 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SPRY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →